Cephalon has reached a $125 million settlement with 48 states in connection with its alleged efforts to delay generic versions of its blockbuster sleep disorder drug Provigil from entering the market, New York Attorney General Eric Schneiderman said.
A widely prescribed diabetes drug failed to reduce deaths or rehospitalizations in a study of patients with advanced heart failure.
After the May 25 announcement that the U.S. Food and Drug Administration was delaying its decision on approval of Sarepta Therapeutics’ eteplirsen for Duchene Muscular Dystrophy (DMD), investors have been waiting often impatiently for news. Although neither the FDA nor Sarepta have said anything, company stock jumped when clinicaltrials.gov, the website that provides information about clinical trials, showed that the company’s Phase III ESSENCE trial for DMD had started recruiting patients.
Myriad Genetics has signed a definitive deal to acquire Assurex Health for $225 million upfront with the potential for $185 million in performance-based milestones.
Banner Health, a non-profit organization that runs a chain of hospitals, said hackers may have gained unauthorized access to patient, physician and beneficiary data.
U.S. government researchers said they have begun their first clinical trial of a Zika vaccine while the Obama administration told lawmakers funds to fight the virus would run out in the coming weeks.
Thirty-three members of the U.S. military, including a pregnant woman, are believed to have contracted the mosquito-borne Zika virus overseas, the Pentagon said.
It may someday be possible to send weak currents of electricity through the scalp during sleep to help improve memory for motor tasks, researchers say.
Genetically modified (GM) mosquitoes could be let loose in Florida’s battle against the Zika virus if regulators approve them, according to British firm Oxitec.